$0.48
Value $16M
CELU and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$0.48
Value $16M
$349.91
Value $318B
Celularity (CELU) has a market value of $16M and UnitedHealth (UNH) $318B. Over the last year, with dividends, CELU moved -68.2% and UNH +12.1%. Dividend yield: CELU none, UNH 2.59%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CELU$16M
UNH$318B
UNH is 20,259 times CELU
Revenue, 12 months
CELU$19M
UNH$450B
UNH is 24,090 times CELU
Net income, 12 months
CELU-$46M
UNH$15.9B
Operating margin
CELU-264.3%
UNH5.3%
269.6 points apart
ROIC
CELU–
UNH11.3%
P/E
CELU–
UNH20.0
Dividend yield
CELU0.0%
UNH2.6%
2.6 points apart
5-year return
CELU-99.3%
UNH-14.7%
84.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CELU-99.3%
UNH-14.7%
| Period | CELUWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -68.2%Price -68.2% | +12.1%Price +9.2% |
| 3 years since November 17, 2023 | -77.0%-38.7% a yearPrice -77.0% | -30.5%-11.4% a yearPrice -34.8% |
| 5 years since November 17, 2021 | -99.3%-63.0% a yearPrice -99.3% | -14.7%-3.1% a yearPrice -22.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CELUCelularityUNHUnitedHealth
| Price | $0.48 | $349.91 |
|---|---|---|
| Market value | $16M | $318B |
| Enterprise value (EV) | $39M | $363B |
| P/E | – | 20.0 |
| P/E, 5-year median | – | 25.0 |
| P/B | – | 3.1 |
| EV/EBIT | – | 15.2 |
| Free cash flow yield | – | 7.2% |
| Revenue, 12 months | $19M | $450B |
|---|---|---|
| Net income, 12 months | -$46M | $15.9B |
| Free cash flow, 12 months | – | $22.8B |
| Earnings per share, 12 months | -$1.69 | $17.52 |
| Revenue growth, year on year | -51.0% | 11.8% |
| Revenue growth a year, past | +13.2%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | 19.2% | 88.3% |
|---|---|---|
| Operating margin | -264.3% | 5.3% |
| Net margin | -245.7% | 3.5% |
| ROIC | – | 11.3% |
| ROE | – | 15.5% |
| Cash | $10M | $28.5B |
|---|---|---|
| Total debt | $61M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | -5,480.9× | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 20,259.4 times Celularity ($16M), at today's prices.
Since November 17, 2021, CELU's price moved -99.3% and UNH's -22.1%. With dividends: CELU -99.3% (-63.0% a year), UNH -14.7% (-3.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Celularity and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was -245.7% for Celularity and 3.5% for UnitedHealth, and the operating margin -264.3% and 5.3%. Revenue was $19M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.